Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Cipla
Daiichi Sankyo
UBS
QuintilesIMS
Chubb
Chinese Patent Office
Cantor Fitzgerald
Teva

Generated: June 18, 2018

DrugPatentWatch Database Preview

Portola Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PORTOLA PHARMS INC, and when can generic versions of PORTOLA PHARMS INC drugs launch?

PORTOLA PHARMS INC has one approved drug.

There are ten US patents protecting PORTOLA PHARMS INC drugs.

There are one hundred and eighteen patent family members on PORTOLA PHARMS INC drugs in thirty-one countries.

Summary for Portola Pharms Inc
International Patents:118
US Patents:10
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Portola Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No 8,691,847 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No 6,376,515 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 RX Yes Yes 9,629,831 ➤ Try a Free Trial ➤ Try a Free Trial
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 RX Yes No 8,557,852 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Portola Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,844,367 Benzamides and related inhibitors of factor Xa ➤ Try a Free Trial
9,061,019 Pharmaceutical salts and polymorphs of a factor Xa inhibitor ➤ Try a Free Trial
7,314,874 Benzamides and related inhibitors of factor Xa ➤ Try a Free Trial
7,342,013 Benzamides and related inhibitors of factor Xa ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Accenture
Citi
Express Scripts
UBS
US Army
Julphar
US Department of Justice
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.